Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

30.0%

3 terminated/withdrawn out of 10 trials

Success Rate

70.0%

-16.5% vs industry average

Late-Stage Pipeline

50%

5 trials in Phase 3/4

Results Transparency

100%

7 of 7 completed trials have results

Key Signals

7 with results

Enrollment Performance

Analytics

Phase 3

5(55.6%)

Phase 1

2(22.2%)

Phase 2

2(22.2%)

9Total

Phase 3(5)

Phase 1(2)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT06664853Phase 3Terminated

Open-Label Extension of EryDex Study IEDAT-04-2022

Role: lead

NCT06193200Phase 3Completed

Evaluate the Neurological Effects of EryDex on Subjects With A-T

Role: lead

NCT01255358Phase 2Completed

Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Teleangiectasia Patients

Role: lead

NCT03563053Phase 3Terminated

Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study

Role: lead

NCT01171807Phase 2Completed

Erythrocytes-Mediated Delivery Of Dexamethasone 21-Phosphate In Steroid-Dependent Ulcerative Colitis

Role: lead

NCT01277289Phase 3Terminated

Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's Disease

Role: lead

NCT02770807Phase 3Completed

Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients

Role: lead

NCT02380924Phase 1Completed

Recovery and Survival of EryDex in Non-patient Volunteers

Role: lead

NCT01925859Phase 1Completed

EryDex Pharmacokinetics in Healthy Volunteers

Role: lead

NCT01942850Completed

International Ataxia Rating Scale in Younger Patients

Role: lead

All 10 trials loaded